![logo](/logos/SPRO.webp)
Spero Therapeutics, Inc.
NASDAQ:SPRO
1.31 (USD) • At close September 6, 2024
Overzicht | Financiële gegevens
Bedrijfsnaam | Spero Therapeutics, Inc. |
Symbool | SPRO |
Munteenheid | USD |
Prijs | 1.315 |
Beurswaarde | 71,074,567 |
Dividendpercentage | 0% |
52-weken bereik | 0.99 - 1.89 |
Industrie | Biotechnology |
Sector | Healthcare |
CEO | Mr. Satyavrat Shukla C.F.A. |
Website | https://sperotherapeutics.com |
An error occurred while fetching data.
Over Spero Therapeutics, Inc.
Spero Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on identifying, developing, and commercializing treatments for multi-drug resistant (MDR) bacterial infections and rare diseases in the United States. The company's product candidates include tebipenem pivoxil hydrobromide (HBr), an oral carbapenem-class antibiotic to treat complicated urinary tract infections, including pyelonephritis for adults;
Vergelijkbare Aandelen
Financiële Gegevens
Cijfers zijn in miljoenen (USD)
Cijfers zijn in miljoenen (USD)